British Pharmacopoeia 2026 Single-user online licence plus BP Archive and British Approved Names (BAN)

Product Description

British Pharmacopoeia 2026 Single-user online licence plus BP Archive and British Approved Names (BAN)

A single-user licence grants access to one designated user and offers a flexible solution – ideal for individuals or smaller organisations. A licence provides access from 1 August 2025 to 31 March 2027 (a total of 20 months).

This edition includes BP Archive (from BP 2014 onwards) and British Approved Names (BAN).

The BP 2026 edition supersedes the BP 2025 and becomes legally effective on 1 January 2026 with all European Pharmacopoeia texts included. Updated annually, the British Pharmacopoeia (BP) is the only comprehensive collection of authoritative official standards for UK pharmaceutical substances and medicinal products. It includes approximately 4,000 monographs, which are legally enforced by the Human Medicines Regulations 2012. Medicinal products or active pharmaceutical ingredients sold or supplied in the UK must comply with the relevant monograph. All monographs and requirements of the European Pharmacopoeia (Ph. Eur.) are reproduced in the BP, making the BP a convenient and fully comprehensive set of standards that can be used across Europe and internationally.

New for the BP 2026 edition

• 19 new BP monographs and 34 new monographs reproduced from the 11th edition of the Ph. Eur., as amended by issues 11.6 to 11.8
• Two new appendices, four supplementary chapters, and six new infrared reference spectra have been added to the collection
• 12 new BPCRS have been produced and referenced
• 131 amended BP monographs
• All monographs from the Ph. Eur. 11th edition and Ph. Eur. issues up to 11.8
• The Ph. Eur. 12th edition, comprising issues 12.1, 12.2 and 12.3, included as an in-year online update

Why BP 2026 matters
The British Pharmacopoeia is the only government-sanctioned pharmaceutical compendium in the UK, carrying full legal authority under the Human Medicines Regulations. BP 2026 ensures that all pharmaceutical substances and products meet current UK and EU quality standards. Trusted worldwide, BP is used in over 100 countries, supporting global compliance and harmonised pharmaceutical practices

Who should use BP 2026:

• Pharmaceutical professionals in research, development, quality control, and manufacturing
• Regulatory authorities, laboratories, universities, and corporate libraries
• Global users who need UK/EU harmonised pharmaceutical standards

Please note: Single-user licences are granted solely to one designated holder. Multi-user licences are available contact us for more details.
May take TSO up to 24 hours to process access details.